Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EKOS CE marks ultrasound-based thrombolytic device

This article was originally published in Clinica

Executive Summary

Ultrasound infusion specialist EKOS has CE marked its EkoSonic endovascular system for sale in Europe. The Bothell, Washington firm says it is the first endovascular device approved for the treatment of pulmonary embolism. The device is used in combination with thrombolytic drugs: it is a catheter incorporating small ultrasound transmitters which condition the clot to absorb the drug more rapidly, causing the clot to dissolve faster than it would with a thrombolytic drug alone. The EkoSonic system was originally designed and approved to dissolve thrombi in the arms and legs; it is approved in the US and Europe for this indication. According to EKOS, pulmonary embolism occurs in approximately one million patients in Europe each year and 600,000 in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel